Opendata, web and dolomites

PREVENT

Prostate cancer extracellular vesicles as biomarkers for nanomedicine treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREVENT project word cloud

Explore the words cloud of the PREVENT project. It provides you a very rough idea of what is the project "PREVENT" about.

diagnostic    ultimately    liquid    diagnosis    flow    anti    curable    strategy    treatment    pc    ing    preclinical    platforms    patient    efficacy    castration    companion    nanomedicine    therapeutic    extracellular    prevent    patients    detected    standard    communication    rational    biomarker    docetaxel    samples    cancer    cytotoxic    prepared    vesicles    worldwide    bodily    cytometry    collect    crpc    drug    composition    disease    created    blood    fluids    antigen    urine    exploited    invasive    fingerprint    monitor    microfluidics    lnps    reduce    sirnas    therapies    combination    prostate    released    resistant    evaluation    tumour    loaded    intercellular    cdx    co    parental    cell    candidates    types    predictability    plasma    nanomedicines    synergistic    psa    agent    immunocapture    immunodetection    deadliest    biopsies    altered    employ    free    cells    therapy    clinical    levels    survival    lethal    stage    lipid    prognosis    genes    containing    nanoparticles    males    evs    excitement    guided   

Project "PREVENT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 228˙421 €
 EC max contribution 228˙421 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-09-14   to  2018-09-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 228˙421.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide. Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease. Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis. However, the application of PSA as a biomarker is associated with predictability issues. Advanced therapies are required for the treatment of CRPC, guided by a reliable companion diagnostic (CDx) test to monitor therapeutic efficacy. The aim of “PREVENT” is to co-develop a nanomedicine-based combination therapy for the treatment of CRPC and a CDx based on extracellular vesicles (EVs). I will employ tumour-targeted nanomedicines to deliver more drug to the tumour and reduce side effects when compared to free drug. The treatment comprises microfluidics-prepared lipid nanoparticles (LNPs) containing siRNAs that target genes involved in CRPC and LNPs loaded with the cytotoxic anti-cancer agent docetaxel to achieve synergistic therapeutic effects. For the CDx test, extracellular vesicles (EVs) have created excitement as possible biomarker candidates. EVs are released by cells as means of intercellular communication and can be detected in bodily fluids. The number of EVs and their composition is altered in CRPC, raising opportunities to exploit them in a CDx test. As EVs provide a fingerprint of their parental cell, EVs can be considered liquid biopsies, providing more information than standard biomarker measurements, and much less invasive than prostate biopsies. I will collect blood and urine samples during the preclinical evaluation of the proposed treatment for analysis using immunocapture and flow cytometry-based immunodetection platforms. The co-development of a nanomedicine combination treatment for CRPC and a CDx test is a rational strategy that has the potential to advance into clinical evaluation and ultimately improve patient survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVENT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREVENT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

PHOTOCARBOX (2020)

Increasing the scope of CO2-utilising photoreactions: asymmetric photosynthesis of amino acids

Read More  

STOPFIRE (2019)

Emergency Decision Support System of Offshore Platform Fires

Read More